id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-254318-w8wrn9lx	Díez, José-María	Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens	2020-05-13		.txt	text/plain	2687	167	48	MATERIAL & METHODS: Gamunex(®)-C and Flebogamma(®) DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against several antigens of human common betacoronaviruses that may crossreact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Gamunex R -C (Grifols Therapeutics, Inc., NC, USA) and Flebogamma R DIF (Instituto Grifols S.A., Barcelona, Spain) IVIGs were tested for crossreactivity against several betacoronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2 antigens, using ELISA techniques. Even with this uncertainty, in the context of the current health emergency (pandemic), the potential of IVIG as a therapy for COVID-19 is already being evaluated in a number of studies involving patients with severe SARS-CoV-2 viral infections including pneumonia [28] [29] [30] . • This is the first time that currently available intravenous immunoglobulins have been reported to contain antibodies that crossreact against antigens of SARS-CoV-2 and other coronaviruses.	./cache/cord-254318-w8wrn9lx.txt	./txt/cord-254318-w8wrn9lx.txt